NCT05989932Completed
Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)
Esperienza Real-world Sull'Uso di Upadacitinib Nel Trattamento Della Dermatite Atopica Moderata-severa Dell'Adulto
Source: ClinicalTrials.gov · Last updated 17 Jul 2025
Brief summary (registry, in English)
Real-world experience on the use of Upadacitinib in the treatment of Adult moderate-severe atopic dermatitis
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 146 (actual)
- First submitted
- 25 Jul 2023
- Start date
- 15 Dec 2021
- Primary completion date
- 19 Apr 2024
- Lead sponsor
- Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05989932
What you commit to
- Study type: Observational
- Participants enrolled: 146
- From 15 Dec 2021 to the primary completion date, 19 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient unable to give informed consent prior to any collection procedure study data
Other
- unable to complete the procedures required for the study
Who the study is looking for
- Age 18 years
- Signature of informed consent
- Diagnosis of moderate and/or severe DA by a dermatologist specialist
- Approval of the compassionate use of upadacitinib
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Irccs Fondazione Policlinico Gemelli Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.